Regeneron Pharma (REGN) Numbers Adjusted at Goldman Sachs
Goldman Sachs maintained a Buy on Regeneron Pharma (NASDAQ: REGN) and trimmed its price target to $353.00 (from $355.00). 2013-2016 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)